Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. REKAMBYS (rilpivirine)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

REKAMBYS (rilpivirine)

Medicine - Posted on Feb 17 2023
Active substance (DCI)
  • rilpivirine
history (2)
  • 2/1/23

    REKAMBYS (rilpivirine) - HIV

    Reassessment and MA amendments. Key points Favourable opinion for maintenance of reimbursement for the treatment of human im...
    CAV :
    54321
    icône flèche
  • 4/21/21

    REKAMBYS (rilpivirine)

    Key points Favourable opinion for reimbursement for the treatment of human immunodeficiency virus type 1 (HIV-1) infection, ...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • J05AG05
Manufacturer
VIIV HEALTHCARE
Presentation

REKAMBYS 900 mg, suspension injectable à libération prolongée
1 flacon(s) en verre de 3 ml avec seringue(s) avec adaptateur(s) pour flacon avec aiguille(s) (CIP : 34009 302 198 7 4)

All our publications
    Drug therapy Immunologic deficiency syndromes Sexually transmitted diseases Virus diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
KLeHzd8f78YL0dyw